|
| Tuesday, December 13, 2016 |
|
|
雅各臣公布完成收购「何济公」之100%权益 |
| 从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业—雅各臣科研制药有限公司（「雅各臣」或「集团」；股份代号：2633）今天宣布完成收购目标集团（由「嘉伦药业有限公司」、「永生药业有限公司」及「香港何济公药厂有限公司」组成），该目标集团拥有传统居家品牌「何济公」之100%权益，总代价为568,000,000港元。 more info >> |
|
| Wednesday, September 23, 2020 |
|
|
Jacobson Pharma Submits Form A1 to Spin-off Its Branded Healthcare Business |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or "the Group"; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong more info >> |
|
| Thursday, August 27, 2020 |
|
|
雅各臣与复星医药合作在香港和澳门供应潜在1,000万剂BioNTech SE 2019冠状病毒病在研疫苗 |
| 于香港从事基要药物及品牌保健护理产品研发、生产、市场推广及销售的领先企业 - 雅各臣科研制药有限公司（「雅各臣」或「集团」;股份代号：2633）今天公布 more info >> |
|
|
雅各臣與復星醫藥合作在香港和澳門供應潛在1,000萬劑BioNTech SE 2019冠狀病毒病在研疫苗 |
| 於香港從事基要藥物及品牌保健護理產品研發、生產、市場推廣及銷售的領先企業 ─ 雅各臣科研製藥有限公司（「雅各臣」或「集團」；股份代號：2633）今天公佈 more info >> |
|
|
Jacobson Pharma Collaborates with Fosun Pharma Group to Supply Potentially 10 Million Doses of BioNTech SE's COVID-19 Vaccine Candidate in Hong Kong and Macau |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or "the Group"; Stock Code: 2633.HK), a leading company engaged in the research, development, production, marketing and sale of essential medicines and branded healthcare products in Hong Kong, today announced the signing of a letter of intent ("Letter of Intent") with Fosun Industrial Co. Ltd. more info >> |
|
| Tuesday, June 30, 2020 |
|
|
雅各臣公佈二零二零財年全年業績 |
| 從事非專利藥及品牌藥品研發、生產、市場推廣及銷售的領先企業─雅各臣科研製藥有限公司（「雅各臣」或「集團」；股份代號：2633）今天公佈公司及其附屬公司（統稱「集團」）於截至二零二零年三月三十一日止年度（「二零二零財年」或「報告期」）的全年業績。 more info >> |
|
|
雅各臣公布二零二零财年全年业绩 |
| 从事非专利药及品牌药品研发、生产、市场推广及销售的领先企业─雅各臣科研制药有限公司（「雅各臣」或「集团」；股份代号：2633）今天公布公司及其附属公司（统称「集团」）于截至二零二零年三月三十一日止年度（「二零二零财年」或「报告期」）的全年业绩。 more info >> |
|
|
Jacobson Pharma Announces FY2020 Annual Results |
| Jacobson Pharma Corporation Limited ("Jacobson Pharma" or the "Company"; Stock Code: 2633), a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, today announced its annual results of the Company and its subsidiaries (collectively the "Group") for the year ended 31 March 2020 (the "FY2020" or the "Reporting Period"). more info >> |
|
| Thursday, February 6, 2020 |
|
|
雅各臣首推家用式流感或病毒測試值得留意 |
| 在武漢新型冠狀病毒肺炎疫情緊張的情況下，股市表現波動，而醫藥股的表現值得留意。當中香港最大的非專利藥公司雅各臣科研製藥（02633）旗下於一月推出的家庭式測試流感及呼吸道病毒的產品可謂及時打了強心針 more info >> |
|
| Wednesday, February 5, 2020 |
|
|
雅各臣科研制药于香港及澳门推出首个家用式流感／呼吸道合胞病毒诊断套件 |
| 从事非专利药及品牌保健护理产品研发、生产、市场推广及销售的领先企业-雅各臣科研制药有限公司（「雅各臣」或「集团」；股份代号：2633）欣然宣布，集团于香港及澳门市场推出其首款流感及呼吸道合胞病毒家用式诊断套件 more info >> |
|
|
|
|
